1. CEO Warner Biddle will present at multiple healthcare conferences. 2. Presentations focus on Kyverna's CAR T-cell therapies for autoimmune diseases. 3. KYV-101 is in late-stage trials for stiff person syndrome and myasthenia gravis. 4. Webcasts of presentations will be accessible via the Kyverna website. 5. Kyverna aims to broaden patient reach with next-gen CAR T-cell therapies.
Kyverna's presentations highlight advancements in their CAR T-cell therapies, boosting investor confidence. Historical upticks in biotech stocks after positive conference presentations support this outlook.
The article's details on conferences and product advancements are likely to attract investor attention and interest in KYTX.
The upcoming conferences in September can influence KYTX's short-term stock movements, similar to market reactions post-conference in biotech firms.
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the following upcoming conferences:
2025 Wells Fargo Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 3rd, 2025
Time: 11:00 a.m. ET
Morgan Stanley 23rd Annual Global Healthcare Conference
Format: Fireside Chat
Date: Monday, September 8th, 2025
Time: 4:05 p.m. ET
H.C. Wainwright 27th Annual Global Investment Conference
Format: Fireside Chat
Date: Tuesday, September 9th, 2025
Time: 11:00 a.m. ET
Live webcasts of the presentations may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. Archived replays of all events will be available on the website for approximately 90 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications for the Company to advance into late-stage development. Additionally, its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats, including efficiently expanding into broader autoimmune indications and the potential to increase patient reach with KYV-102 using its proprietary whole blood rapid manufacturing process. For more information, please visit https://kyvernatx.com.
Contacts:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
